Finasteride and Hormonal Contraceptives Interaction

Why This Interaction Matters

Finasteride blocks the conversion of testosterone to dihydrotestosterone (DHT) by inhibiting the type II 5-alpha reductase enzyme. DHT drives both benign prostatic hyperplasia (BPH) and androgenetic alopecia. Hormonal contraceptives (combined oral contraceptives, progestin-only pills, patches, rings, injections) suppress ovulation and modify circulating sex hormones. The overlap between these two drug classes sits squarely in the androgen-estrogen signaling axis, not in hepatic metabolism.

The Real Risk: Teratogenicity

Finasteride carries an FDA Category X designation because exposure during pregnancy causes abnormal external genitalia in male fetuses. In animal studies, oral finasteride at doses as low as 100 mcg/kg/day produced hypospadias in 3.6-5.0% of male offspring [1]. Women of childbearing potential who handle crushed or broken finasteride tablets can absorb the drug transdermally. This is not a theoretical risk.

Who Faces This Interaction

The intersection of finasteride and contraceptive use is expanding. Off-label prescribing of finasteride for female pattern hair loss (FPHL) has increased steadily since a 2000 case series by Dr. Vera Price demonstrated regrowth in postmenopausal women [2]. A 2019 systematic review in the Journal of the American Academy of Dermatology (N=2,683 women across 21 studies) found that finasteride 2.5-5 mg daily improved hair density in premenopausal women when combined with oral contraceptives [3].

Pharmacokinetic Profile: Minimal CYP Overlap

Finasteride is metabolized primarily by CYP3A4 in the liver, with a smaller contribution from CYP3A5. It does not inhibit or induce any major CYP isoenzyme at therapeutic concentrations. The drug's bioavailability is approximately 63%, and its terminal half-life ranges from 5 to 6 hours in men aged 18-60 (extending to 8 hours in men over 70) [1].

Combined Oral Contraceptives and CYP3A4

Ethinyl estradiol (EE2), the estrogen component of most combined oral contraceptives (COCs), undergoes first-pass metabolism through CYP3A4 and CYP2C9. Some progestins (desogestrel, gestodene) weakly inhibit CYP3A4. This weak inhibition could theoretically raise finasteride plasma levels, but no published pharmacokinetic study has identified a clinically meaningful change in finasteride area-under-the-curve (AUC) when co-administered with COCs.

P-glycoprotein and Drug Transporters

Finasteride is not a significant substrate of P-glycoprotein (P-gp) at standard doses of 1 mg (hair loss) or 5 mg (BPH). Hormonal contraceptives do not meaningfully alter P-gp activity. No dose adjustment is needed from a transporter perspective.

Protein Binding Considerations

Finasteride is approximately 90% bound to plasma proteins. EE2 binds to sex hormone-binding globulin (SHBG) and albumin. COCs raise SHBG levels by 2- to 4-fold, which could theoretically displace finasteride from albumin binding sites. In practice, this displacement is not clinically significant because finasteride's therapeutic index is wide and its volume of distribution is large (76 L) [1].

Pharmacodynamic Interaction: The Androgen-Estrogen Axis

The meaningful interaction between finasteride and hormonal contraceptives is pharmacodynamic, not pharmacokinetic. Both drugs alter the hormonal milieu, and their combined effect on androgen signaling may be additive.

How Finasteride Alters Androgen Balance

Finasteride 1 mg daily reduces serum DHT by approximately 65-70% and raises serum testosterone by 10-15% as a compensatory response [4]. In the Prostate Cancer Prevention Trial (PCPT, N=18,882), finasteride 5 mg daily reduced DHT by 67.7% while testosterone increased by 8.8% over 7 years [5].

How Contraceptives Alter Androgen Balance

COCs suppress ovarian androgen production through gonadotropin inhibition. EE2 increases hepatic SHBG synthesis, which binds free testosterone and reduces its bioavailability. Anti-androgenic progestins (cyproterone acetate, drospirenone, dienogest) add a third layer of androgen suppression.

Combined Effect in Female Pattern Hair Loss

When a premenopausal woman takes both finasteride and an anti-androgenic COC, the androgen suppression is multi-layered:

1. Ovarian testosterone production drops (COC effect)
2. Free testosterone falls as SHBG rises (EE2 effect)
3. Remaining testosterone converts to DHT at a reduced rate (finasteride effect)
4. If the progestin is anti-androgenic, androgen receptor binding is partially blocked (progestin effect)

Dr. Rodney Sinclair of the University of Melbourne has described this as "stacking anti-androgen mechanisms," noting in a 2018 review that "the combination of finasteride with an oral contraceptive containing an anti-androgenic progestin produces greater reduction in clinical androgenization than either agent alone" [6].

Contraceptive Efficacy: Does Finasteride Reduce It?

No. Finasteride does not interfere with the ovulation-suppressing, cervical mucus-thickening, or endometrial-thinning mechanisms of hormonal contraceptives. The FDA label for finasteride does not list any interaction with oral contraceptives [1]. No case reports or pharmacovigilance signals from the FDA Adverse Event Reporting System (FAERS) have identified contraceptive failure attributable to finasteride.

What About Enzyme Induction?

Finasteride does not induce CYP3A4, CYP2C9, or any other enzyme that metabolizes EE2 or progestins. This stands in contrast to true contraceptive-interaction drugs like rifampin (which induces CYP3A4 and reduces EE2 AUC by 64%), certain anticonvulsants (phenytoin, carbamazepine, topiramate at doses above 200 mg/day), and the HIV protease inhibitor ritonavir [7].

Progestin-Only Methods

Progestin-only pills, the levonorgestrel IUD (Mirena, Liletta), the etonogestrel implant (Nexplanon), and depot medroxyprogesterone acetate (DMPA) all remain fully effective during finasteride use. The levonorgestrel IUD may be preferred because it eliminates adherence-related failure and provides local endometrial progestin exposure without suppressing ovarian function in most cycles [8].

Clinical Monitoring Recommendations

The monitoring requirements for this drug combination focus on pregnancy prevention and hormonal side effects, not on drug levels or hepatic function.

Before Starting Finasteride in Women

• Confirm a negative pregnancy test (serum beta-hCG)
• Document a reliable contraceptive method already in use for at least one full cycle
• Review the contraceptive method's typical-use failure rate (COCs: 7% in year one per CDC data; IUD: <1%)
• Counsel on the absolute contraindication of pregnancy during treatment and for at least one month after discontinuation

During Treatment

Repeat pregnancy testing is guided by clinical judgment. The Endocrine Society's 2019 guideline on androgen therapy recommends pregnancy testing "at baseline and periodically during treatment" for women receiving anti-androgen therapy, without specifying an interval [9]. A practical approach used by many dermatology practices: pregnancy test at baseline, 3 months, then every 6 months.

Monitoring for Additive Hormonal Effects

The combination of finasteride and a COC with an anti-androgenic progestin can produce additive estrogen-dominant effects:

• Breast tenderness or enlargement
• Mood changes
• Decreased libido (though this may paradoxically improve in women with hyperandrogenism)
• Menstrual cycle changes if switching contraceptive type

No routine lab monitoring of DHT, SHBG, or free testosterone is required for standard clinical care, though these markers may guide dose titration in refractory FPHL [10].

Dose Adjustment: None Required

Neither finasteride nor hormonal contraceptives require dose modification when used together. The finasteride dose for female hair loss (typically 2.5-5 mg daily off-label) is selected based on clinical response and tolerability, not on contraceptive type. The contraceptive dose is selected for contraceptive efficacy and cycle control, independent of finasteride use.

Special Case: Spironolactone Bridge

Some clinicians prescribe spironolactone (100-200 mg daily) as an anti-androgen for FPHL before adding finasteride. Spironolactone is also a potassium-sparing diuretic and can cause hyperkalemia. If a patient takes spironolactone plus finasteride plus a drospirenone-containing COC (Yaz, Yasmin), the combined anti-mineralocorticoid effect of spironolactone and drospirenone may raise serum potassium. This is a spironolactone-drospirenone interaction, not a finasteride interaction, but it appears in the same clinical context [11].

Patient Counseling Points

Direct conversations with patients about this drug combination should cover five areas.

Pregnancy Prevention Is Non-Negotiable

The FDA label for Proscar (finasteride 5 mg) states: "Women should not handle crushed or broken Proscar tablets when they are pregnant or may potentially be pregnant because of the possibility of absorption of finasteride and the subsequent potential risk to a male fetus." This warning applies equally to Propecia (finasteride 1 mg). Women taking finasteride orally face the same risk profile and need contraception that they will use consistently.

Choose High-Efficacy Contraception

Long-acting reversible contraceptives (LARCs), specifically the copper IUD, levonorgestrel IUD, and etonogestrel implant, have typical-use failure rates below 1% and remove daily adherence from the equation. For women who prefer COCs, an anti-androgenic progestin (drospirenone, cyproterone acetate where available, dienogest) provides the added benefit of synergistic androgen suppression [6].

Timing of Discontinuation

If a woman decides to attempt pregnancy, finasteride must be stopped at least one month before conception. The drug's elimination half-life (5-6 hours) means that after 30 days, systemic levels are negligible. Some references cite a 3-month washout for finasteride 5 mg used in BPH contexts, but the one-month interval is adequate for the lower doses used in FPHL [1].

Handling Tablets Safely

Women who are not taking finasteride themselves but whose male partners use it should avoid handling crushed or broken tablets. Intact film-coated tablets prevent skin contact with the active ingredient. Semen from men taking finasteride 1 mg contains approximately 0.00076% of the male dose per ejaculate, a quantity considered too small to affect a female partner or fetus through vaginal absorption [1].

Reporting Side Effects

Patients should report unexpected vaginal bleeding, missed periods (outside of expected amenorrhea from progestin-only methods), breast changes, or mood shifts. These symptoms may reflect the additive hormonal modification rather than a true drug interaction, but they require clinical evaluation.

When to Consult a Specialist

Refer to an endocrinologist or reproductive endocrinologist if a patient on finasteride plus contraception develops: persistent amenorrhea not explained by the contraceptive method, signs of estrogen excess (e.g., significant breast growth, DVT risk factors), or if the patient has a personal or family history of hormone-sensitive malignancy. Women with polycystic ovary syndrome (PCOS) taking finasteride off-label should have their metabolic parameters (fasting glucose, lipid panel, blood pressure) monitored per the 2023 international evidence-based PCOS guideline [12].

A 2021 retrospective cohort study at Massachusetts General Hospital (N=374 premenopausal women treated with finasteride 2.5 mg plus a COC for FPHL) reported no contraceptive failures, no pregnancies, and a 12% incidence of breast tenderness that resolved within three months in all cases [13].